BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Akorn, Inc. investors (“Akorn ” or the “Company”) (NASDAQ: AKRX) concerning the Company and its officers’ possible violations of federal securities laws.
On February 26, 2018, Fresenius SE & Co. KGaA announced that it was conducting an investigation into Akorn’s, product development, and alleged breaches of FDA data integrity requirements. Fresenius further stated the “consummation of the [merger] transaction may be affected if the closing conditions under the merger agreement are not met.”
On this news, Akorn’s share price fell $11.63, or nearly 38%, to close at $18.65, on February 27, 2018, thereby injuring investors.
If you purchased Akorn securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.